These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update. Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Tleyjeh IM; Kashour Z; Damlaj M; Riaz M; Tlayjeh H; Altannir M; Altannir Y; Al-Tannir M; Tleyjeh R; Hassett L; Kashour T Clin Microbiol Infect; 2021 Feb; 27(2):215-227. PubMed ID: 33161150 [TBL] [Abstract][Full Text] [Related]
5. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials. Vela D; Vela-Gaxha Z; Rexhepi M; Olloni R; Hyseni V; Nallbani R Br J Clin Pharmacol; 2022 May; 88(5):1955-1963. PubMed ID: 34713921 [TBL] [Abstract][Full Text] [Related]
7. Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials. Selvaraj V; Khan MS; Bavishi C; Dapaah-Afriyie K; Finn A; Lal A; Mylonakis E Lung; 2021 Jun; 199(3):239-248. PubMed ID: 34050796 [TBL] [Abstract][Full Text] [Related]
8. Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis. Godolphin PJ; Fisher DJ; Berry LR; Derde LPG; Diaz JV; Gordon AC; Lorenzi E; Marshall JC; Murthy S; Shankar-Hari M; Sterne JAC; Tierney JF; Vale CL PLoS One; 2022; 17(7):e0270668. PubMed ID: 35802687 [TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
10. Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials. Gupta S; Padappayil RP; Bansal A; Daouk S; Brown B J Investig Med; 2022 Jan; 70(1):55-60. PubMed ID: 34561232 [TBL] [Abstract][Full Text] [Related]
11. Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence. Sweeney DA; Lobo SM; Póvoa P; Kalil AC Clin Microbiol Infect; 2024 May; 30(5):611-618. PubMed ID: 38182048 [TBL] [Abstract][Full Text] [Related]
12. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials. Lin WT; Hung SH; Lai CC; Wang CY; Chen CH Int Immunopharmacol; 2021 Jul; 96():107602. PubMed ID: 33812260 [TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Khan FA; Stewart I; Fabbri L; Moss S; Robinson K; Smyth AR; Jenkins G Thorax; 2021 Sep; 76(9):907-919. PubMed ID: 33579777 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19: A systematic review and meta-analysis. Zhang J; Chen C; Yang Y; Yang J Medicine (Baltimore); 2022 Mar; 101(9):e28967. PubMed ID: 35244063 [TBL] [Abstract][Full Text] [Related]
16. Tocilizumab in the treatment of COVID-19-a meta-analysis. Avni T; Leibovici L; Cohen I; Atamna A; Guz D; Paul M; Gafter-Gvili A; Yahav D QJM; 2021 Nov; 114(8):577-586. PubMed ID: 34010403 [TBL] [Abstract][Full Text] [Related]
17. Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review. Wang Y; Zhu K; Dai R; Li R; Li M; Lv X; Yu Q Front Pharmacol; 2021; 12():804250. PubMed ID: 35126138 [TBL] [Abstract][Full Text] [Related]
18. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M; JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of interleukin-6 receptor antagonists in adult patients admitted to intensive care unit with COVID-19: A systematic review and Peng R; Yang T; Tong Y; Wang J; Zhou H; Yang M; Zhu J; Yang L; Shi Z; Liu Y Prev Med Rep; 2023 Aug; 34():102276. PubMed ID: 37309358 [TBL] [Abstract][Full Text] [Related]
20. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Snow TAC; Saleem N; Ambler G; Nastouli E; Singer M; Arulkumaran N Intensive Care Med; 2021 Jun; 47(6):641-652. PubMed ID: 34019122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]